A breast cancer awareness campaign by the research advocacy group Susan G. Komen for the Cure overstated the benefit that mammograms have on survival rates of women with breast cancer, researchers say in a new editorial.

Komen's messages in its 2011 campaign stated that 98 percent of women who get the screening tests survive at least five years, while 23 percent of women who do not get mammogramssurvive that long — a difference of 75 percentage points.

In an online editorial in the British Medical Journal, however, two researchers argue that randomized controlled trials have shown mammograms reduce the risk of dying from the disease by far less. For example, among those with breast cancer who are in their 60s, the risk of dying over a 10-year period is reduced from 83 percent to 56 percent — a difference of 27 percentage points.

"The ad campaign doesn’t present screening as a genuine choice — it suggests you'd have to be crazy or stupid not to get screened," said editorial author Dr. Steven Woloshin, a professor at Dartmouth College's Geisel School of Medicine. Whether or not to get screened is actually a "genuine decision, because there are benefits and harms," Woloshin said.

A Komen spokesman defended the campaign statements. “The numbers are not in question. Early detection allows for early treatment, which gives women the best chance of surviving breast cancer,” Komen vice president Chandini Portteus said.

The reasons for screening
Woloshin called whether to get screened a personal decision that should be based on factors including age and family history. For example, younger women are less likely to have breast cancer in general, but those with a strong family history of the disease might want to be screened earlier.

Screening has been associated with a decrease in mortality due to breast cancer, but the decrease is not as dramatic as Komen suggested, said Harvard Medical School radiologist Dr. Daniel Kopans.

Randomized control trials have found, in general, that screening reduces the number of lives lost to breast cancer by approximately 30 percent, said Kopans. In the U.S., deaths due to breast cancer also have decreased by about 30 percent since screening was instated in the 1980s.

"Thirty percent fewer women die each year from breast cancer than would have without screening," Kopans said, noting that part of this benefit is due to improvements in treatments for earlier stages of the disease. "Therapy saves lives when you find cancer early," he said.

Still, critics of mammograms say they can produce false alarms that lead to unnecessary biopsies. Portteus' reply: "Everyone agrees that mammography isn’t perfect, but it’s the best widely available detection tool that we have today."

A misleading advertisement
Komen's campaign was promoted last October and was designed and funded by the Komen foundation, which has raised over $1.9 billion for breast cancer awareness, research and support to patients.

Woloshin and his co-author, Lisa M Schwartz of Dartmouth, argue that the survival statistics used to support the Koman message about screening were misleading. This was a "disingenuous representation of statistics," Woloshin said, because screening adds a "lead time" between when cancer is found and when it becomes dangerous.

For instance, the authors wrote, consider a group of women who aren't screened but find a breast lump at age 67, and are subsequently diagnosed. If these women all die at age 70, their five-year survival rate is 0 percent. Now imagine another group of women, who were screened and diagnosed with breast cancer at age 64. If these women also all die at age 70, their five-year survival rate is 100 percent — even though both groups lived to the same age.

Organizations pushing cancer screening "have their work cut out for them," Kopans said. "They're trying to convince women to take a test that nobody wants to take." In this case Komen exaggerated, he said.

The problem of overdiagnosis
The issue of screening is further made controversial by the problem of overdiagnosis: Some women are treated with chemotherapy or surgery even though their cancers would never become dangerous or affect their lives, Woloshin said.

Randomized control trials have found that overdiagnosis occurs in 1 percent to 10 percent of screening cases, Kopans said. He said, however, this risk is worth the number of lives that are ultimately saved by screening.

Women should base their decisions on whether to be screened by weighing the facts and consulting with their doctors, Woloshin said. The Komen website does provide accurate information on the benefits and harms of screening, he said.

Woloshin said he hopes Komen reconsiders their use of statistics if they run a similar ad campaign this October.

More from MyHealthNewsDaily:

• The 10 Deadliest Cancers and Why There's No Cure
• 10 Do's and Don'ts to Reduce Your Risk of Cancer
• 7 Cancers You Can Ward Off with Exercise

Some participants in Susan G. Komen for the Cure events, like this run in San Diego, have reconsidered their support in the wake of a controversy over Planned Parenthood funding this week.

Fierce controversy over a policy that cut -- then apparently restored -- funding for Planned Parenthood by the Susan G. Komen for the Cure breast-cancer charity has left some longtime supporters of both groups feeling whipsawed by the fallout.

Fans who’ve worn pink ribbons and jogged in Race for the Cure runs and those who’ve supported women’s reproductive health services had mixed reactions following news Friday that Komen had agreed to amend criteria that would have barred Planned Parenthood from future grants.

Some Komen supporters said the organization had alienated them forever by cutting funding in the first place based on perceived political pressure from anti-abortion groups.

“It’s difficult for me to want to continue to support Komen now,” said Peg Callaway, 63, a lawyer from Omak, Wash. “It makes me mistrust the organization.”

As the Associated Press first reported Tuesday, Komen had adopted criteria excluding Planned Parenthood from future grants for breast-cancer screening because it was under government investigation, citing a probe launched by a Florida congressman at the urging of anti-abortion groups.

The decision was made in December, but became public this week, igniting a firestorm of protest. By Friday, Komen appeared to back off the plan, saying it would fund existing Planned Parenthood grants, and that the agency would be eligible for future grants. Some critics said it wasn't clear how the decision actually would affect future grants.

Still, Callaway remained suspicious.

“They’ve done a lot of damage to themselves,” she said.

Others, however, said that Komen’s quick reversal made them want to give an agency another chance. Dina Lalli-Bender, 47, of Laurel Springs, N.J., said she participated last year in a Race for the Cure event in Philadelphia in memory of close friends and family members lost to breast cancer.

“I’ll continue to do the run now,” said Lalli-Bender, a senior manager at a trade show labor firm. “Now that they’ve changed their minds, maybe they’ve seen that people were outraged by it.”

But avid Komen supporters who had been cheered by what they saw as a strong stand against Planned Parenthood were dismayed that the agency appeared to back off.

“I was very disappointed to hear that the decision was reversed so quickly,” said Rita C. Hruschak, 69, a retired nurse from Webster, N.Y. “It was barely warming up the griddle. The hope for a positive change to some good morals was lost too soon.”

She pointed to Planned Parenthood’s huge base of support -- including $3 million and 10,000 Facebook fans raised during the three days of the controversy -- as evidence that the agency could fund breast cancer screenings on its own. Planned Parenthood previously had received about $700,000 a year from Komen.

“So you know, they don’t really need Komen’s help or support,” she said.

In an informal msnbc.com poll Thursday, more than 6,000 respondents considered whether the controversy would alter their donations to either group.

Some 73 percent of people of took the poll said it would increase their donations to Planned Parenthood, while about 17 percent said it would increase funding to Komen. Nine percent of respondents said they don’t donate to either group.

Only 1 percent said they’d continue donating to both.

Has the Komen decision, and then apparent reversal, changed how you feel about the organization? Tell us on Facebook.

Related:

Komen backs off decision on funding cuts

Too little, too late for Komen, bioethicist says

Under fire, Komen CEO denies politics in Planned Parenthood cuts